MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Takeda, a Japanese pharmaceutical company, has agreed to a deal worth up to $1.7 billion with Iambic Therapeutics to expand its use of artificial intelligence in drug discovery, reinforcing a broader push to modernize early-stage research. Under the agreement, Takeda will use Iambic’s AI-driven platform to design and optimize small-molecule drug candidates, with an initial focus on multiple therapeutic targets. The structure includes upfront payments, research funding, and milestone-based fees tied to development progress. Takeda will also gain access to Iambic's NeuralPLexer model that predicts how drug molecules bind to proteins. The approach to use AI predictions fast-tracks discovery and reduces timelines, saving months of traditional lab work and creating something that could not have been done before.
More
Posted by MedCloudInsider Editors on 02/09/20260 comments
Brainomix, a global leader in AI-powered imaging, has launched a next-generation stroke AI platform called Brainomix 360 Next Generation featuring novel net water uptake technology, unveiling the system at the International Stroke Conference (ISC). The platform is designed to enhance clinicians' assessment of ischemic stroke by providing more detailed insights into brain tissue damage and edema through advanced imaging analysis. The technology helps clinicians more accurately assess tissue viability and treatment options, particularly in time-critical stroke cases.
More
Posted by MedCloudInsider Editors on 02/03/20260 comments
Reprocell, an integrated stem cell and gene-editing service provider, has launched StemEdit, a new clinical gene-editing system licensed from Profulent, called OpenCRISPR-1™. The service is intended to support pharmaceutical, biotech and academic researchers developing cell and gene therapies by providing edited iPSC lines suitable for preclinical and clinical applications. StemEdit is designed to improve precision, reproducibility and turnaround time compared with traditional gene-editing workflows.
More
Posted by MedCloudInsider Editors on 02/03/20260 comments
Renew Biotechnologies, a nucleic-acid-based clinical development company, has advanced its epigenetic diagnostics portfolio with the launch of Path Fertility’s NOA Guide, a tool designed to support clinical decision-making for men with non-obstructive azoospermia (NOA). The diagnostic applies epigenetic analysis to assess testicular tissue and help clinicians determine the likelihood of sperm retrieval, informing treatment planning and patient counseling. The guide is intended to provide more objective insight than conventional assessments, which often rely on limited biomarkers or invasive procedures. The collaboration advances clinical applications that helps partners deliver emerging biological insights into clinically deployable diagnostics.
More
Posted by MedCloudInsider Editors on 02/03/20260 comments
A new survey from Kipu Health, a leader in behavioral health technology, finds that artificial intelligence is rapidly becoming a clinical and workforce imperative in behavioral health. The research shows growing adoption of AI tools to support documentation, care coordination and operational efficiency, as providers contend with rising demand for services and persistent staffing shortages. Respondents indicated that AI is increasingly seen not as an experimental technology, but as a necessary component of delivering sustainable, high-quality behavioral health care.
More
Posted by MedCloudInsider Editors on 01/27/20260 comments
Lunai Bioworks, an AI-powered drug discovery and biodefense company, has expanded its NIH-funded artificial intelligence research program into a commercial drug discovery effort focused on alcohol use disorder (AUD). The company is applying its AI-enabled platform, which models neural circuits and behavior, to identify and validate new therapeutic candidates targeting the underlying biology of addiction. The expansion marks a transition from government-backed research into a commercially driven development program toward candidate nomination and downstream development.
More
Posted by MedCloudInsider Editors on 01/27/20260 comments
AIDS Healthcare Foundation (AHF) has modernized its contract management processes using CloudMoyo’s generative AI-powered IntelliDoc Analyze (CDA) platform. CloudMoyo is a global AI-first consulting solutions firm. The platform is designed to improve efficiency and accelerate document analysis and data extraction. The solution uses AI to analyze contracts, extract key terms, identify obligations and flag potential issues, helping AHF manage agreements more consistently as it operates across multiple regions and regulatory environments. The platform enables faster review cycles while improving visibility into contractual commitments.
More
Posted by MedCloudInsider Editors on 01/20/20260 comments
Katalyze AI, builder of Agentic AI systems for pharmaceutical manufacturing, has launched Katalyst, an agentic AI platform designed specifically for pharmaceutical manufacturing operations. The AI agent is built to help manufacturing teams accelerate scientific decision-making and operate with grounded insights for production data. The platform is designed to operate within existing manufacturing systems, supporting use cases such as deviation analysis, root-cause identification and continuous process optimization while respecting regulatory constraints. Katalyst connects to existing operational systems to combine statistical analysis, advanced data visualizations with scientifically grounded reasoning towards improved production yields.
More
Posted by MedCloudInsider Editors on 01/20/20260 comments
MediKarma, a leader in Agentic AI for healthcare, has launched what it describes as healthcare’s first Agentic AI Licensing Program, designed to give providers and partners access to pre-validated AI agents focused on disease management. The model allows healthcare organizations to license individual agents tailored to specific conditions, rather than building or training systems from scratch. MediKarma's agents are designed to support care coordination, patient engagement and longitudinal disease monitoring while operating within defined clinical and governance boundaries.
More
Posted by MedCloudInsider Editors on 01/12/20260 comments
Impilo, the creator of a hybrid healthcare delivery operating system, has introduced TaylorAI, a digital health concierge agent built to help patients navigate setting up monitoring devices and assist with troubleshooting. The AI agent is designed to answer common questions, assist with scheduling, guide patients through how to use their monitoring devices and explain to patients exactly what is happening in real-time.
More
Posted by MedCloudInsider Editors on 01/12/20260 comments
Function, a medical and health company on a mission to empower humanity to reach 100 years, has launched the Function Connector, an integration with Claude, the large language model developed by Anthropic. The integration allows members to authorize Claude to access lab results and to provide guided health advice that is based on these results. Function said the goal is to make members understand their health-related matters in a simple way that can guide smarter, healthier choices.
More
Posted by MedCloudInsider Editors on 01/12/20260 comments
Recent research reveals that Biotronik Neuro's remote monitoring with real-time visibility into spinal cord stimulation (SCS) usage can support a more effective, long-term approach to managing implanted neurostimulation devices. Biotronik is a leading medical device company aimed at developing improvements for heart and blood vessel diseases. The research examined how continuous data on stimulation patterns and patient engagement can help clinicians better understand therapy adherence, optimize programming and identify issues earlier than traditional follow-up methods. Researchers claim that the approach addresses a long-standing gap in post-implant care, where limited visibility has made it difficult to assess how devices are actually used outside the clinic.
More
Posted by MedCloudInsider Editors on 01/05/20260 comments